Tivic Health Systems rises after deal for late-stage immunotherapy drug

Valion Bio

12/02/2025 19:22

** Shares of medical device maker Tivic Health Systems
 TIVC.O  more than double to 49 cents; set to record the largest
single-day percentage gain
    ** TIVC says it has acquired exclusive worldwide rights from
Statera Biopharma  STAB.PK  to a late-stage immunotherapy drug
called entolimod, which is used for the treatment of acute
radiation syndrome (ARS), a condition caused by exposure to high
doses of ionizing radiation
    ** The deal includes an initial payment of $1.2 million in
equity and $300,000 in cash to Statera
    ** Drug has the potential to be approved by the U.S. FDA
within two years - TIVC
    ** The FDA has granted "fast track" and "orphan drug"
designation to entolimod for the treatment of ARS - TIVC
    ** The global ARS market is estimated to be valued at $5.2
billion in 2024 with a compound annual growth rate of 5% from
2024 to 2031 - TIVC
    ** TIVC fell 80.7% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))